{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:52:35Z","timestamp":1790743955238,"version":"4.1.0"},"reference-count":57,"publisher":"Informa UK Limited","issue":"12","funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc.","doi-asserted-by":"publisher","award":["None"],"award-info":[{"award-number":["None"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2017,12,2]]},"DOI":"10.1080\/17474086.2017.1391088","type":"journal-article","created":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T11:29:41Z","timestamp":1507894181000},"page":"1107-1119","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":22,"title":["Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States"],"prefix":"10.1080","volume":"10","author":[{"given":"Andrzej J.","family":"Jakubowiak","sequence":"first","affiliation":[{"name":",","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Houisse","sequence":"additional","affiliation":[{"name":",","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"M\u00e1jer","sequence":"additional","affiliation":[{"name":",","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1gnes","family":"Benedict","sequence":"additional","affiliation":[{"name":",","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Campioni","sequence":"additional","affiliation":[{"name":",","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumeet","family":"Panjabi","sequence":"additional","affiliation":[{"name":"Global Health Economics, Amgen Inc., South San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[{"name":",","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,11,30]]},"reference":[{"key":"e_1_3_2_2_1","volume-title":"Surveillance, Epidemiology, and End Results Program","author":"SEER","year":"2017","unstructured":"SEER. Surveillance, Epidemiology, and End Results Program. Myeloma: Stat Fact Sheets; 2017. Accessed Oct 4. http:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0547"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.346"},{"issue":"19531","key":"e_1_3_2_6_1","article-title":"Real world impact of treatment-induced peripheral neuropathy (TIPN) on patient reported outcomes (PROs) in patients with multiple myeloma (MM) in the United States","volume":"33","author":"Walker M","year":"2015","unstructured":"Walker M, Cong Z, Knopf K, et al. Real world impact of treatment-induced peripheral neuropathy (TIPN) on patient reported outcomes (PROs) in patients with multiple myeloma (MM) in the United States. J Clin Oncol. 2015;33(suppl; abstr e19531). DOI: 10.1200\/jco.2015.33.15_suppl.e19531","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_7_1","unstructured":"Panjabi S Song X Wilson K et al. Costs associated with treatment induced peripheral neuropathy in patients with multiple myeloma by lines of therapy. Abstract presented at: 58th Annual Meeting & Exposition. San Diego CA. December 3-6 2016.)."},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4086"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-065888"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2014.11.019"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00464-7"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30578-8"},{"key":"e_1_3_2_13_1","unstructured":"Amgen Press Release. Second phase 3 study shows KYPROLIS\u00ae (Carfilzomib) regimen significantly improves overall survival in patients with relapsed multiple myeloma.\u00a0[cited 2017 Oct 11]. Available from:\u00a0http:\/\/wwwext.amgen.com\/media\/news-releases\/2017\/07\/second-phase-3-study-shows-kyprolis-carfilzomib-regimen-significantly-improves-overall-survival-in-patients-with-relapsed-multiple-myeloma\/."},{"key":"e_1_3_2_14_1","unstructured":"Ludwig H Moreau P Dimopoulos M et al. Health related quality of life results from the open-label randomized phase iii endeavor trial evaluating carfilzomib and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Abstract presented at: 58th Annual Meeting & Exposition. San Diego CA. 2016 Dec 3-6. (2016)."},{"key":"e_1_3_2_15_1","article-title":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology","volume":"2","author":"NCCN","year":"2017","unstructured":"NCCN. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Multiple Myeloma. 2017;v2.2018. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf","journal-title":"Multiple Myeloma"},{"key":"e_1_3_2_16_1","unstructured":"Human Mortality Database. University of California Berkeley (USA) and Max Planck Institute for Demographic Research (Germany). [cited 27 April 2017]. Available at: www.mortality.org or www.humanmortality.de."},{"key":"e_1_3_2_17_1","unstructured":"Latimer N NICE DSU Technical Support Document 14: survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data. June 2011 .[updated 2013 Mar; cited 2017 Jan 30]. Available from: http:\/\/www.nicedsu.org.uk\/Survival-analysis-TSD(2892878).htm."},{"key":"e_1_3_2_18_1","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1182\/blood.V126.23.3026.3026","article-title":"Final analysis of overall survival from the phase 3 panorama 1 trial of panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma","volume":"126","author":"San-Miguel J","year":"2015","unstructured":"San-Miguel J, Hungria V, Yoon S, et al. Final analysis of overall survival from the phase 3 panorama 1 trial of panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2015;126:3026.","journal-title":"Blood"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30026"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X16639900"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2016.1194278"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.01.019"},{"key":"e_1_3_2_23_1","volume-title":"RED BOOK","author":"Truven Health Analytics","year":"2013","unstructured":"Truven Health Analytics. RED BOOK. Ann Arbor, MI: Truven Health Analytics; 2016. Ann Arbor, MI; 2013. [cited 2017 Mar 31]. Available from: http:\/\/sites.truvenhealth.com\/redbook\/index.html."},{"key":"e_1_3_2_24_1","volume-title":"National statistics by principal diagnosis code","author":"HCUPnet National Inpatient Sample (NIS), Agency for Healthcare Research and Quality (AHRQ)","year":"2013","unstructured":"HCUPnet National Inpatient Sample (NIS), Agency for Healthcare Research and Quality (AHRQ). National statistics by principal diagnosis code. Rockville, MD: Agency for Healthcare Research and Quality; 2013. [cited 2016 Mar 29]. Available from: http:\/\/hcupnet.ahrq.gov\/"},{"key":"e_1_3_2_25_1","volume-title":"Data on File. Retrospective study of healthcare utilization and costs in patients with multiple myeloma using Truven MarketScan data through","author":"Amgen Inc","year":"2014","unstructured":"Amgen Inc. Data on File. Retrospective study of healthcare utilization and costs in patients with multiple myeloma using Truven MarketScan data through. Thousand Oaks, CA, USA: Amgen Inc; 2014 Dec."},{"key":"e_1_3_2_26_1","volume-title":"Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy","author":"National Institute for Health and Care Excellence (NICE) technology appraisal guidance (TA171)","year":"2009","unstructured":"National Institute for Health and Care Excellence (NICE) technology appraisal guidance (TA171). Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy. England, UK: NICE; 2009. [updated 2014 Apr; cited 2016 Sep 21]. https:\/\/www.nice.org.uk\/guidance\/ta171"},{"key":"e_1_3_2_27_1","volume-title":"ID663 Single technology appraisal (STA) manufacturer\u2019s submission","author":"Novartis","year":"2015","unstructured":"Novartis. Panobinostat for treating multiple myeloma in people who have received at least one prior therapy. In: ID663 Single technology appraisal (STA) manufacturer\u2019s submission. Basel, Switzerland: Novartis; 2015.[cited 2016 Sept 21]. Available from: http:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-tag477\/documents"},{"key":"e_1_3_2_28_1","unstructured":"pan-Canadian Oncology Drug Review (pCODR). pan-Canadian Oncology Drug Review Final Economic Guidance Report Lenalidomide (Revlimid) for multiple myeloma 2013; cited 2016 Sep 21]. Available from: https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/pcodr-revlimid-mm-fn-egr.pdf."},{"key":"e_1_3_2_29_1","unstructured":"pan-Canadian Oncology Drug Review (pCODR). pan-Canadian Oncology Drug Review Final Economic Guidance Report Pomalidomide (Pomalyst) for multiple myeloma 2014; [cited 2016 Sept 21]. Available from: https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/pcodr-pomalyst-mm-fn-egr.pdf."},{"key":"e_1_3_2_30_1","unstructured":"Scottish Medicines Consortium (SMC). SMC Advice: lenalidomide (Revlimid). 2015; [cited 2016 Sep 21]. Available from: https:\/\/www.scottishmedicines.org.uk\/SMC_Advice\/Advice\/1096_15_lenalidomide_Revlimid\/lenalidomide_Revlimid."},{"key":"e_1_3_2_31_1","volume-title":"Panobinostat for treating multiple myeloma after at least 2 previous treatments","author":"National Institute for Health and Care Excellence (NICE) technology appraisal guidance [TA 380]","year":"2016","unstructured":"National Institute for Health and Care Excellence (NICE) technology appraisal guidance [TA 380]. Panobinostat for treating multiple myeloma after at least 2 previous treatments. England, UK: NICE; 2016. [cited 2016 Sep 21]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta380"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-12-35"},{"key":"e_1_3_2_33_1","volume-title":"Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib","author":"National Institute for Health and Care Excellence (NICE) technology appraisal guidance [TA338]","year":"2015","unstructured":"National Institute for Health and Care Excellence (NICE) technology appraisal guidance [TA338]. Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib. England, UK: NICE; 2015. [cited 2017 Jan 30]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta338"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.0534"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e31815c31a7"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2011.0251"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-2-90"},{"issue":"573","key":"e_1_3_2_38_1","article-title":"Adjusting the value of a statistical life for age and cohort effects","volume":"90","author":"Aldy J","year":"2008","unstructured":"Aldy J, Viscusi W. Adjusting the value of a statistical life for age and cohort effects. Rev Econ Stat. 2008;90(573\u2013581).","journal-title":"Rev Econ Stat"},{"key":"e_1_3_2_39_1","unstructured":"Amgen Press Release. Long-term analysis of phase 3 head-to-head study confirms Kyprolis\u00ae (carfilzomib) regimen extends overall survival in patients with relapsed multiple myeloma. [cited 2017 October 4]. Available from: http:\/\/wwwext.amgen.com\/media\/news-releases\/2017\/08\/longterm-analysis-of-phase-3-headtohead-study-confirms-kyprolis-carfilzomib-regimen-extends-overall-survival-in-patients-with-relapsed-multiple-myeloma\/."},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321"},{"issue":"4","key":"e_1_3_2_41_1","first-page":"204","article-title":"Estimating the costs of therapy in patients with relapsed and\/or refractory multiple myeloma: a model framework","volume":"8","author":"Roy A","year":"2015","unstructured":"Roy A, Kish JK, Bloudek L, et al. Estimating the costs of therapy in patients with relapsed and\/or refractory multiple myeloma: a model framework. Am Health Drug Benefits. 2015;8(4):204\u2013215.","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.390"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.380"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.3805"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2015.02.003"},{"key":"e_1_3_3_1_2_2_1","volume-title":"National statistics by principal diagnosis code","author":"HCUPnet National Inpatient Sample (NIS), Agency for Healthcare Research and Quality (AHRQ)","unstructured":"HCUPnet National Inpatient Sample (NIS), Agency for Healthcare Research and Quality (AHRQ). National statistics by principal diagnosis code. Rockville, MD: Agency for Healthcare Research and Quality; 2013. http:\/\/hcupnet.ahrq.gov\/. Accessed 29 March 2016.)."},{"key":"e_1_3_3_1_2_3_1","volume-title":"Retrospective study of healthcare utilization and costs in patients with multiple myeloma using Truven MarketScan Data Through","author":"Amgen Inc","year":"2014","unstructured":"Amgen Inc. Data on File. Retrospective study of healthcare utilization and costs in patients with multiple myeloma using Truven MarketScan Data Through December 2014. Thousand Oaks, CA, USA: Amgen Inc; 2015.)."},{"key":"e_1_3_3_1_2_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-643320"},{"key":"e_1_3_3_1_2_5_1","unstructured":"ClinicalTrials.gov. Available at: https:\/\/www.clinicaltrials.gov\/ct2\/ show\/NCT02597062?term=carfilzomib+cyclophosphamide+dexametha sone+relapsed&rank=2. Accessed 30 May 2017.)."},{"key":"e_1_3_3_1_2_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"},{"key":"e_1_3_3_1_2_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"e_1_3_3_1_2_8_1","volume-title":"Open-Label,Multicenter, Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with at Least 2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma","author":"Chari A","year":"2015","unstructured":"Chari A, Lonial S, Suvannasankha A et al. Open-Label,Multicenter, Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with at Least 2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma. Abstract number 508. Presented at: 57th Annual Meeting & Exposition of the American Society of Hematology; Orlando, FL. 7 December 2015.)."},{"key":"e_1_3_3_1_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01120-4"},{"key":"e_1_3_3_1_2_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654"},{"key":"e_1_3_3_1_2_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"e_1_3_3_1_2_12_1","volume-title":"Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM). Abstract number 304","author":"Lacy M","unstructured":"Lacy M, LaPlant B, Richardson P et al. Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM). Abstract number 304. Presented at: 56th Annual Meeting & Exposition of the American Society of Hematology; San Francisco, CA. 6 December 2014\u20139.)."},{"key":"e_1_3_3_1_2_13_1","volume-title":"RED BOOK. Ann Arbor, MI","author":"Truven Health Analytics","year":"2013","unstructured":"Truven Health Analytics 2013. RED BOOK. Ann Arbor, MI: Truven Health Analytics; 2016. Ann Arbor, MI http:\/\/sites.truvenhealth.com\/red book\/index.html. Accessed 31 March 2017.). 13. Onyx data on file. (2016)."},{"key":"e_1_3_3_1_2_14_1","unstructured":"Onyx data on file. (2016)."}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2017.1391088","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T18:51:01Z","timestamp":1770403861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2017.1391088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,30]]},"references-count":57,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12,2]]}},"alternative-id":["10.1080\/17474086.2017.1391088"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2017.1391088","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,30]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-09-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-10-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-11-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}